NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
Clinical Trials
16 trialsNCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT01205828 2025-02-12
ABT-888 and Temozolomide for Liver Cancer
Georgetown University
Phase 2 Terminated
NCT03556384 2024-11-04
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
University of California, San Diego
Phase 2 Active not recruiting
NCT05661643 2024-03-15
GIST
Asan Medical Center
Phase 2 Recruiting
NCT04984733 2023-11-29
ELEVATE
University of Southampton
Phase 2 Recruiting
NCT04166435 2023-09-06
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
Yale University
Phase 2 Completed
NCT05136326 2023-03-01
CATARTIC
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Recruiting
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT03832621 2022-04-04
MAYA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02414009 2021-09-09
CAPTEM
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT02231762 2019-05-06
SONNET
Ipsen
Phase 2 Completed
NCT01051596 2019-04-02
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
Georgetown University
Phase 2 Completed
NCT03204032 2017-06-29
A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor
ChineseAMS
Phase 2 Unknown
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00005597 2013-01-03
S9926 Temozolomide in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
SWOG Cancer Research Network
Phase 2 Completed